Given that persistent cancer cells constitute a major cause of cancer treatment failure, these data collectively indicated that functional inhibition of the NRF2 pathway had the potential to be a novel strategy for OAC and possibly GOJ adenocarcinoma patients that have become resistant to HER2-targeted therapies. The gene discussed is ERBB2; the disease is adenocarcinoma.